Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis.
SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).
Kakeya
Hiroshi
H
Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. kakeya@nagasaki-u.ac.jp
Miyazaki
Yoshitsugu
Y
Senda
Hisato
H
Kobayashi
Tsutomu
T
Seki
Masafumi
M
Izumikawa
Koichi
K
Yanagihara
Kazunori
K
Yamamoto
Yoshihiro
Y
Tashiro
Takayoshi
T
Kohno
Shigeru
S
D000666:Amphotericin B / Q000494:pharmacology*; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001231:Aspergillus flavus / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D054714:Echinocandins / Q000494:pharmacology*; D055666:Lipopeptides; D008074:Lipoproteins / Q000494:pharmacology*; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D000077551:Micafungin; D051379:Mice; D011090:Polyenes / Q000494:pharmacology*; D016896:Treatment Outcome
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D011090:Polyenes; C068538:liposomal amphotericin B; C115650:SPA S 843; D000666:Amphotericin B; D000077551:Micafungin